Abstract
good clinical results,2 we therefore chose these devices for dispensing budesonide supplied in metered-dose inhalers. The children had to be able to operate a spacer device, and preference was given to those capable of adequately measuring their peak expiratory flow rate with a meter.
Over 1000 children with asthma are followed in our clinic (including approximately 240 new patients every year). The 15 children studied entered the trial over a period of 15 months. These 15 children were all those followed in our outpatient clinic who received continuous treatment with budesonide for more than three years and who fulfilled the above criteria.
The budesonide was administered in two puffs twice daily, each puff containing 50 μg, for a total daily dose of 200 micrograms. During the first two years, a Nebuhaler (AB Draco, Lund, Sweden) was used; thereafter, a multispacer was substituted (Medic-aid, Sussex, United Kingdom) because it was considered easier for the young children to use.
The research protocol was reviewed and approved by the hospital's ethics committee for clinical investigation, and written informed consent was obtained from the parents of each child.
Study Design
Since a placebo-controlled trial was not feasible in these children because of the severity of their asthma, the study was an open trial. Budesonide therapy was started after a run-in period of one month. At the beginning of this period, cromolyn sodium therapy was discontinued. During this period, both terbutaline and theophylline were allowed but prednisone was not. A week after therapy with budesonide was begun, the parents were asked to discontinue the use of theophylline, but they could give terbutaline as needed.
If an exacerbation of asthma occurred after budesonide therapy began, the parents were instructed to add terbutaline to the regimen if the child was not taking it, and then theophylline. If the asthma was severe, prednisone could be given for three to five days.
After the second year of follow-up, an acute exacerbation of asthma was managed by a new treatment protocol that included a temporary increase in the dosage of budesonide, to 100 to 200 μg four times daily, preceded by two puffs of terbutaline. After one to three days, the dosage of inhaled budesonide was decreased to 100 μg three times daily, and one to three days later it was decreased to the maintenance dose of 100 μg twice daily.
With this regimen almost all exacerbations of asthma were controlled with no need for prednisone.
Twice annually, at the end of each year of budesonide therapy and during the summer months (June through September), stopping budesonide therapy was proposed to the parents if the child's clinical condition would permit it.
The study began in February 1986. The children were examined monthly during the first year of treatment, and thereafter every three months.
Assessment of Clinical Response
The parents were asked to keep a daily record of the child's symptoms during the run-in period and then during the entire first year of budesonide therapy. Daily records were kept thereafter only during exacerbations of asthma. From these records we determined the number of days on which the child had symptoms of asthma (diurnal and nocturnal cough, wheezing, and dyspnea), the use of bronchodilator drugs and prednisone, the daily peak expiratory flow rates (measured with a Mini Wright Peak Flow Meter [Clement Clarke International, London]), the number of days on which the child took an antibiotic drug for concurrent illnesses, and possible side effects.
At each visit we measured the peak expiratory flow rate and determined whether wheezing was present at the physical examination (a score of 0 was assigned if wheezing was absent, a score of 1 if it was mild, and a score of 2 if it was severe). The parents' and the physicians' opinions of the child's overall clinical condition were also recorded (scores ranged from 0, if asthma was absent, to 3, if it was severe). Compliance with budesonide administration was assessed by determining the ratio of the amount of drug remaining in the inhaler to the amount prescribed; the mean (±SD) ratio was 82 ±9 percent.
Assessment of Drug Safety
At each visit, a trained nurse measured the child's standing height with a stadiometer and his or her weight while the child wore minimal clothing. Weight, height, and height velocity were plotted on appropriate growth charts developed by Tanner et al8. Since the height velocity during the year before budesonide treatment was not known, we compared the height velocity during the later years of follow-up with that during the first year of follow-up.
Bone age was determined at the start of the study and yearly thereafter from x-ray films of the left wrist, interpreted according to the radiographic atlas of Greulich and Pyle9.
Pituitary-adrenal function was evaluated at the same time by measuring serum cortisol concentrations at 8 a.m. after an overnight fast and 60 minutes after intravenous administration of 0.25 mg of corticotropin (Cortrosyn, Organon International NV, Oss, the Netherlands). The morning dose of budesonide was given only after blood samples were obtained for the serum cortisol measurement.
Toward the end of the study we also measured serum cortisol concentrations in blood samples collected every 30 minutes for 24 hours and 24-hour urinary cortisol excretion in 11 of the 15 children (mean age, 9 years; range, 7 to 11). This group had been treated with budesonide for three to five years. Cortisol was measured while the children continued to take their usual twice-daily doses of budesonide. At the end of the study a slit-lamp eye examination was performed in all the children.
Cortisol Measurements
Serum and urinary cortisol concentrations were measured with commercial radioimmunoassay kits (Coat-A-Count, Diagnostic Products, Los Angeles). All samples from 24-hour studies of each child were analyzed at the same time. In normal children of comparable age, the fasting serum cortisol concentration at 8 a.m. ranged from 4 to 23 μg per deciliter (110 to 635 nmol per liter) in our laboratory, the serum cortisol 60 minutes after corticotropin administration ranged from 18 to 50 μg per deciliter (497 to 1380 nmol per liter), and the mean 24-hour urinary cortisol excretion ranged from 12 to 55 μg per day (33 to 152 nmol per day). The interassay and intraassay coefficients of variation for serum cortisol concentrations ranged from 4.5 to 6.5 percent and from 3 to 8 percent, respectively.
Statistical Analysis
The results during budesonide therapy were compared with those during the three-month period preceding the beginning of the one-month run-in period, or with those during the run-in period before the initiation of budesonide therapy. Values are expressed as means ±SD. Differences within groups were compared by paired t-tests. All tests were two-tailed, and P values below 0.05 were considered to indicate statistical significance.
RESULTS
The 15 children --10 boys and 5 girls, 2 to 7 years old at the start of the study (mean, 4 years 10 months) --were followed for at least 3 and as long as 5 years (mean ±SD, 4 ±1).
During this period, most of them received budesonide continuously in a dose of 100 μg twice daily. After four years of treatment, three children (9, 10, and 11 years old) required a dose of 150 μg twice daily.
Clinical Response
As compared with the control of asthma during the one-month run-in period of severe asthma immediately before the start of budesonide therapy, control improved during the first month after the beginning of therapy. During this month, there was a 58 percent decrease in the number of days with symptoms of asthma, a 75 percent decrease in the use of terbutaline, theophylline, and prednisone, a 71 percent decrease in the score for wheezing, and a 17 percent increase in the mean peak expiratory flow rate (in the 12 children who were capable of using a flow meter correctly) ( Figure 1FIGURE 1 Changes in Asthmatic Status before and during Inhaled Budesonide Therapy in 15 Children with Severe Asthma.). The improvement was maintained throughout the period of treatment. There was also a large decrease in the number of exacerbations of asthma, the number of visits to the emergency room, and the number of hospitalizations (Table   1TABLE 1 Control of Asthma in Children Treated with Budesonide.). Both the parents and the physicians noted substantial overall improvement in the control of asthma. The number of days during which the children took an antibiotic drug decreased by 73 percent (Table 1) . During the entire study period, six children did not need any antibiotic treatment for concurrent illnesses and four took antibiotics on only one occasion.
During the entire treatment period, discontinuation of budesonide therapy was attempted on 46 occasions in all 15 children, but the drug could be discontinued in only 2 of them (after four years of treatment). All other attempts were followed by a recurrence of symptoms. Forty of the 44 unsuccessful attempts (91 percent) failed within 2 to 30 days (mean, 14) after budesonide was discontinued.
Assessment of Drug Safety Linear Growth
Before budesonide therapy began, the height and weight of the children were within the normal ranges for their ages ( Figure 2FIGURE 2 
Changes in Height and
Weight during Inhaled Budesonide Therapy.). In contrast, their bone age was less than their chronologic age ( Figure 3FIGURE 
DISCUSSION
Budesonide is a nonhalogenated corticosteroid with high topical antiinflammatory potency and low systemic bioavailability11,12. The prolonged administration of budesonide to children with asthma led to an improvement in airway hyperresponsiveness accompanied by clinical control of asthma13-15.
The results of this study confirm the long-term efficacy of inhaled budesonide in young children, albeit in an uncontrolled study, and in addition demonstrate that the treatment does not impair growth or inhibit pituitary-adrenal function. In the selected children with severe asthma whom we studied, treatment with a relatively low dose of budesonide was associated with an excellent clinical response, beginning soon after the initiation of treatment and lasting throughout the follow-up period. Budesonide therapy was necessary to control asthma during the follow-up period, because its discontinuation in the 15 children (46 attempts) resulted in a recurrence of asthma in all but 2 children.
The most important safety consideration in young children treated with inhaled corticosteroids for long periods is the effect of the treatment on their growth and pituitaryadrenal function. The adverse effects of inhaled corticosteroid therapy are dosedependent16-18. Treatment with beclomethasone in a dose of 300 to 600 μg per day for more than one year did not adversely affect the final height of the children3-7. Similarly, most children treated with budesonide for a year grew normally14,15,19. There may, however, be some slowing of linear growth, especially when relatively high doses of inhaled corticosteroids are used. For example, children given 800 μg of budesonide per day for 12 weeks had a decrease in linear growth, whereas those treated with 200 or 400 μg per day did not16,17. In another study, treatment with 200 to 800 μg of beclomethasone per day had an adverse effect on growth20. However, the impairment of growth in the children in that study might have been due to physiologic deceleration of their growth rate or, in the older children, to a delay of the onset of puberty, which has been reported in children with asthma3,21,22. In our study, the linear growth of the children was normal for their age at all times. Their bone age was slightly delayed before they received budesonide, but this delay in bone age was shortened slightly during treatment. With respect to another skeletal complication of corticosteroid therapy --bone disease --in a recent study in children, inhaled beclomethasone in doses up to 800 μg per day had no effect on bone mineralization or bone resorption23.
In several long-term studies of children with asthma treated with beclomethasone or budesonide in doses up to 800 mg per day, pituitary-adrenal function was normal as reflected by normal base-line serum cortisol concentrations,7,24 normal serum cortisol responses to corticotropin,5,7,24 and normal 24-hour urinary excretion of cortisol24,25.
However, other studies of beclomethasone, given in doses of 400 to 800 μg per day, found some evidence of adrenal suppression --most often, decreased urinary cortisol excretion10,26-30. Treatment with higher doses (1000 to 1800 μg per day) of either corticosteroid usually caused adrenal suppression18,29. In our study, the results of all tests of pituitary-adrenal function were normal at all times, indicating the absence of pituitary or adrenal suppression, but unfortunately not all the tests were carried out before budesonide therapy was started.
Giving patients with asthma inhaled corticosteroids predisposes them to colonization of the oropharynx with Candida albicans7,31. This colonization and the dysphonia that may accompany it are often related to the dose of the corticosteroid and the frequency of its administration32-34. The occurrence of this side effect is usually reduced by using spacer devices, which reduce the amount of corticosteroid deposited in the oropharynx35. Our use of a spacer and lower doses of budesonide could account for the absence of oral candidiasis in any of the children studied.
Treatment with oral corticosteroids may induce the formation of posterior subcapsular cataracts36. The formation of a cataract in a child treated with inhaled budesonide has been reported, although the child had also received short courses of oral corticosteroid therapy37. No cataracts were found in any of our patients.
We conclude that prolonged administration of inhaled budesonide in a relatively low dose of 200 μg per day to young children with severe asthma is not only effective but also safe, as demonstrated by their normal linear growth and normal pituitary-adrenal function.
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